Semaglutide 2.4mg Shows Significant Long-Term Cardiometabolic Benefits in Real-World Obesity

Obesity and overweight are global health crises, significantly increasing the risk of type 2 diabetes, cardiovascular disease, and other metabolic complications. While clinical trials have demonstrated the efficacy of GLP-1 receptor agonists like semaglutide for weight management and metabolic improvements, these controlled environments may not fully reflect real-world outcomes. This study aimed to evaluate the long-term cardiometabolic effects of semaglutide 2.4 mg in a diverse patient population within a real-world U.S. healthcare setting.

Over the 2-year follow-up period, patients treated with semaglutide 2.4 mg demonstrated substantial and sustained improvements in cardiometabolic parameters compared to the control group. The mean body weight reduction was 15.2% from baseline at 24 months (p<0.001), significantly greater than the 2.1% reduction observed in matched controls. The most impactful finding was a 21% reduction in the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, in the semaglutide group compared to controls (HR 0.79, 95% CI 0.71-0.88, p<0.001). Additionally, systolic blood pressure decreased by an average of 7.8 mmHg and diastolic blood pressure by 4.2 mmHg (p<0.001 for both), alongside significant improvements in lipid profiles, including a 10.5% reduction in triglycerides and a 5.3% increase in HDL-C. Glycated hemoglobin (HbA1c) also saw a mean reduction of 1.1% in patients with prediabetes or type 2 diabetes (p<0.001), further demonstrating improved glycemic control.